This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
marijuana: Archive
Cannabis Stock CRLBF Gains 25% in a Month: Time to Buy, Sell or Hold?
by Sundeep Ganoria
CRLBF surges 25% this month on reform hopes, but revenue declines, margin pressure and stiff competition cloud its outlook.
TLRYPositive Net Change GTBIFPositive Net Change CRLBFPositive Net Change CURLFPositive Net Change
marijuana
Cannabis Stock CRON Trades Near 52-Week High: How to Play
by Sundeep Ganoria
Cronos trades near its 52-week high as international growth boosts sales, but losses and stiff competition weigh on its outlook.
CRONPositive Net Change TLRYPositive Net Change HITIPositive Net Change CURLFPositive Net Change
marijuana medical
Cannabis Stock VRNOF Soars 178% in a Month: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Verano's stock has surged 178% in a month on reform hopes, but pricing pressure and stiff competition test its momentum.
ACBPositive Net Change GTBIFPositive Net Change VRNOFPositive Net Change CURLFPositive Net Change
marijuana medical
3 Cannabis Stocks to Watch After Trump's Marijuana Rescheduling Signal
by Sundeep Ganoria
Trump's marijuana rescheduling remarks reignite cannabis optimism, putting Village Farms, Canopy Growth and High Tide in focus.
CGCPositive Net Change VFFNegative Net Change HITIPositive Net Change
marijuana medical pot-stocks
Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification
by Sweta Killa
Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.
MJPositive Net Change CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change YOLOPositive Net Change CNBSPositive Net Change MSOSPositive Net Change WEEDPositive Net Change
etfs marijuana
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
by Sundeep Ganoria
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
CRBPPositive Net Change CGCPositive Net Change TLRYPositive Net Change HRMYNegative Net Change GTBIFPositive Net Change
biotechs marijuana medical pot-stocks
Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change CURLFPositive Net Change
earnings marijuana medical pot-stocks
Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?
by Sundeep Ganoria
Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.
TLRYPositive Net Change GTBIFPositive Net Change CRLBFPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?
by Sundeep Ganoria
GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.
ACBPositive Net Change GTBIFPositive Net Change CRLBFPositive Net Change CURLFPositive Net Change
marijuana medical
Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change CRLBFPositive Net Change
marijuana medical pot-stocks
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
by Sundeep Ganoria
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
JAZZPositive Net Change AXSMNegative Net Change HRMYNegative Net Change
biotechs marijuana medical
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Could the New Federal Bill Derail the U.S. Hemp Industry?
by Sundeep Ganoria
A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.
CGCPositive Net Change TLRYPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?
by Sundeep Ganoria
Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change VFFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?
by Sundeep Ganoria
After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change VFFNegative Net Change
marijuana medical pot-stocks
Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical pot-stocks
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVOPositive Net Change LLYPositive Net Change CRBPPositive Net Change SKYENegative Net Change
biotechs marijuana medical pharmaceuticals
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
by Sundeep Ganoria
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
SNYPositive Net Change NVOPositive Net Change CRBPPositive Net Change
marijuana medical
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.
PMPositive Net Change JAZZPositive Net Change CRBPPositive Net Change TLRYPositive Net Change
marijuana medical pot-stocks
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZPositive Net Change PBYINegative Net Change NTLAPositive Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.
IIPRNegative Net Change LAMRNegative Net Change EPRNegative Net Change
cannabis finance marijuana reit
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXNegative Net Change
biotechs cancer cannabis earnings-preview marijuana medical
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMPositive Net Change JAZZPositive Net Change CRBPPositive Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
JAZZPositive Net Change KNSANegative Net Change CRDLNo Net Change
biotechs marijuana medical pot-stocks
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZPositive Net Change HRMYNegative Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals